RYE, N.Y., July 28 /PRNewswire/ -- Curemark, LLC (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that Saint Peter's University Hospital in New Brunswick, New Jersey, is participating in the company's Phase III clinical trials for CM-AT, Curemark's autism treatment.
Saint Peter's is affiliated with the Drexel University College of Medicine in Philadelphia. Drexel University College of Medicine began enrolling patients in the CM-AT autism study earlier this year. Curemark's clinical trial program for CM-AT now encompasses a total of 13 sites nationwide.
CM-AT, which has received Fast Track status from the FDA, is based on Curemark's research that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein. The inability to digest protein affects the availability of amino acids, the building blocks of chemicals essential for brain function. If approved, CM-AT will be one of the first therapies to address the underlying physiology of autism.